GLP-1 originator (Ozempic 2017, Wegovy 2021). Wegovy holds about 65% of US new prescriptions, though Lilly overtook Novo in share outside the US in early 2026. CagriSema (cagrilintide + semaglutide) FDA submission filed December 2025. Novo Holdings acquired Catalent for $16.5B in 2024 to expand fill-finish capacity from 2026.